A detailed history of Ameritas Investment Partners, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 21,405 shares of NBIX stock, worth $2.46 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
21,405
Previous 21,943 2.45%
Holding current value
$2.46 Million
Previous $3.03 Million 2.64%
% of portfolio
0.1%
Previous 0.11%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$130.86 - $143.19 $70,402 - $77,036
-538 Reduced 2.45%
21,405 $2.95 Million
Q1 2024

May 13, 2024

BUY
$130.4 - $143.74 $32,469 - $35,791
249 Added 1.15%
21,943 $3.03 Million
Q4 2023

Feb 14, 2024

SELL
$106.07 - $132.76 $21,956 - $27,481
-207 Reduced 0.95%
21,694 $2.86 Million
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $231,853 - $288,768
-2,466 Reduced 10.12%
21,901 $2.46 Million
Q2 2023

Aug 11, 2023

SELL
$89.53 - $104.87 $19,965 - $23,386
-223 Reduced 0.91%
24,367 $2.3 Million
Q1 2023

May 10, 2023

SELL
$94.11 - $123.02 $27,291 - $35,675
-290 Reduced 1.17%
24,590 $2.49 Million
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $30,308 - $36,085
284 Added 1.15%
24,880 $2.97 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $70,771 - $82,905
-769 Reduced 3.03%
24,596 $2.61 Million
Q4 2021

Feb 11, 2022

BUY
$79.65 - $106.22 $23,417 - $31,228
294 Added 1.17%
25,365 $2.16 Million
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $41,711 - $47,930
-484 Reduced 1.89%
25,071 $2.41 Million
Q2 2021

Aug 06, 2021

SELL
$89.43 - $102.27 $21,910 - $25,056
-245 Reduced 0.95%
25,555 $2.49 Million
Q1 2021

May 14, 2021

BUY
$87.57 - $119.4 $2.26 Million - $3.08 Million
25,800 New
25,800 $2.51 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.